EnVivo’s Alzheimer’s Drug Could Be On Fast Track To Approval
BOSTON (CBS) — EnVivo Pharmaceuticals of Watertown is about to begin new tests on a promising treatment for Alzheimer’s Disease.
WBZ NewsRadio 1030’s New England Business Editor Anthony Silva reports
EnVivo CEO Dr. Deborah Dunsire says the company is launching a Phase 3 international clinical test of its therapy called Encenicline.
“We’re looking at focusing it on the memory loss aspect of Alzheimer’s Disease, and facilitating people’s ability to access their memories and be able to live more normally for a longer period of time,” she says.
Dunsire says the Food and Drug Administration has given these tests a special protocol assessment, meaning the therapy could win quicker approval if the tests are successful.
She tells WBZ she’s very excited that EnVivo will be able to bring a new day to patients with Schizophrenia and Alzheimer’s Disease.
“Schizophrenia patients, because their disease sometimes robs them of the ability to adequately organize themselves, or maintain work or live alone, and if we can help them with that, we can free them up to be more independent,” she says. “With Alzheimer’s patients, if they’re able to use their memories more effectively, they can live either alone or in home care for longer.”
The Phase 3 clinical trial will include some 1600 people in several countries.